Congratulations to Woody Emlen and the rest of the Taligen Therapeutics team on their excellent Emerging Company Profile appearing in yesterday’s BioCentury’s Bernstein Report on BioBusiness. Great coverage not only for Taligen but this widely distributed periodical shines a great light upon Colorado life sciences.
“Taligen Therapeutics, Inc. is taking a two approaches to modulating complement for inflammatory diseases. The company thinks its lead antibody, TA-106, can modulate the pro-inflammatory system while still preserving the body’s natural immune response. A second program targets complement-mediated inflammation locally to reduce systemic toxicity and the amount of inhibitory protein needed for therapeutic effect…”